scispace - formally typeset
Open AccessJournal ArticleDOI

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.
About
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.

read more

Citations
More filters
Journal ArticleDOI

Aspirin in Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Review of the Balance of Evidence from Reviews of Randomized Trials

TL;DR: Novel methods used to re-evaluate the balance of benefits and harms of aspirin using evidence from randomised controlled trials, systematic reviews and meta-analyses indicate small absolute effects of aspirin relative to the burden of these diseases.

Health Care Guideline Diagnosis and Management of Type 2 Diabetes Mellitus in Adults

TL;DR: Copies of this ICSI Health Care Guideline may be distributed by any organization to the organization’s employees but, except as provided below, may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.
Journal ArticleDOI

Variation in Restarting Antithrombotic Drugs at Hospital Discharge After Intracerebral Hemorrhage

TL;DR: Variation in clinical practice and lack of consistent associations with restarting antithrombotic drugs after ICH reflect current knowledge and support the need for randomized controlled trials to resolve this dilemma.
Journal ArticleDOI

Lifestyle interventions for secondary disease prevention in stroke and transient ischaemic attack: a systematic review

TL;DR: There is currently insufficient high quality research to support lifestyle interventions post-stroke or TIA on mortality, CVD event rates and cardio-metabolic risk factor profiles.
Journal ArticleDOI

The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.

TL;DR: The first clinical trial, called ADAPTABLE, will randomly assign 20,000 subjects with established coronary heart disease to either low dose (81 mg) or high dose (325 mg), and should be able to finally answer which dosage of aspirin is best for patients with established cardiovascular disease.
References
More filters
Journal ArticleDOI

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.
Related Papers (5)